2 Discovery of Cep-1347/Kt-7515, an Inhibitor of the Jnk/Sapk Pathway for the Treatment of Neurodegenerative Diseases

Progress in Medicinal Chemistry

Volumn 40, Issue C, 2002, Pages 23-62

  Saporito, Michael S ^b   Hudkins, Robert L ^a   Maroney, Anna C ^b  

^a Departments of Medicinal Chemistry   (United States)

^b CEPHALON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAZOLE DERIVATIVE; CEP 1347; ENZYME INHIBITOR; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; NOOTROPIC AGENT; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE 1;

ANIMAL; APOPTOSIS; DEGENERATIVE DISEASE; DISEASE MODEL; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; PARKINSON DISEASE; REVIEW;

ANIMALS; APOPTOSIS; CARBAZOLES; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; HUMANS; INDOLES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASES; NEURODEGENERATIVE DISEASES; NOOTROPIC AGENTS; PARKINSON DISEASE;

EID: 0036988312     PISSN: 00796468     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6468(08)70081-X     Document Type: Article

References (174)

1. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science 267 (1995) 1456-1462
2. Johnson E.M., DeckwerTh T.L., and Deshmukh M. Neuronal death in developmental models: possible implications in neuropathology. Brain Pathology 6 (1996) 397-409
3. Oppenheim R.W. Cell death during development of the nervous system. Ann. Rev. Neurosci. 14 (1991) 453-501
4. Honig L.S., and Rosenburg R.N. Apoptosis and neurological disease. Am. J. Med. 108 (2000) 317-330
5. Bergeron L., and Yuan J. Sealing one's fate: control of cell death in neurons. Curr. Opin. Neuronal. 8 (1998) 55-63
6. Smale G., Nichols N.R., Brady D.R., Finch C.E., and Horton Jr. W.E. Evidence for apoptotic cell death in Alzheimer's disease. Exp. Neurol. 133 (1995) 225-230
7. Li W.P., Chan W.Y., Lai H.W.L., and Yew D.T. Terminal dUTP Nick End Labeling (TUNEL) positive cells in the different regions of the brain in normal aging and Alzheimer patients. J. Mol. Neurosci. 8 (1997) 75-82
8. Miellce K., and Herdegen T. JNK and p38 stresskinases - degenerative effectors of signal-transduction-cascades in the nervous system. Prog. Neurobiol. 61 (2000) 45-60
9. Estus S., Zaks W.J., Freeman R.S., Gruda M., Bravo R., and Johnson E.M. Altered gene expression in neurons during programmed cell death: Identification of c-Jun as necessary for neuronal apoptosis. J. Cell. Biol. 127 (1999) 1717-1727
10. Schlingensiepen K.H., Wallnik F., Kunst M., Schlingensiepen R., Herdengen T., and Brysch W. The role of Jun transcription factor expression and phosphorylation in neuronal differentiation, neuronal cell death, and plastic adaptations in vivo. Cell. Mol. Neurobiol. 14 (1994) 487-505
11. Ham J., Babij C., Whitfield J., Pfarr C.M., Lallemand D., Yaniv M., and Rubin L.L. A c-Jun dominant negative mutant protects sympathetic neurons against programmed cell death. Neuron 14 (1995) 927-939
12. Hibi M., Lin A., Stneal T., Minden A., and Karin M. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-jun activation domain. Genes Dev. 7 (1993) 2135-2148
13. Derijard B., Hibi M., Wu I.-H., Barrett T., Su B., Deng T., Karin M., and Davis R.J. JNK1: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76 (1994) 1025-1037
14. Kyriakis J.M., Banerjee P., Nikolakaki E., Dal T., Rubie E.A., Ahmad M.F., Avruch J., and Woodgett J.R. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369 (1994) 156-160
15. Watson A., Eilers A., Lallemand D., Kyriakis J., Rubin L.L., and Ham J. Phosphorylation of c-Jun is necessary for apoptosis induced by survival signal withdrawal in cerebellar granule neurons. J. Neurosci. 18 (1998) 751-762
16. Le-Ntculescu H., Bonfoco E., Kasuya Y., Claret F.X., Green D.R., and Karin M. Withdrawal of survival factors results in activation of the JNK pathway in neuronal cells leading to Fas ligand induction and cell death. Mol. Cell. Biol. 19 (1999) 751-763
17. Deijard B., Raingeaud J., Barrett T., Wu I.H., Han J., Ulevitch R.J., and Davis R.J. Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science 267 (1995) 682-685
18. Sanchez I., Hughes R.T., Mayer B.J., Yee K., Woodgett J.R., Avruch J., Kyriakis J.M., and Zon L.I. Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun. Nature 372 (1994) 794-798
19. Lin A., Minden A., Martinetto H., Claret F.X., Lange-Carter C., Mercurio F., Johnson G.L., and Karin M. Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2. Science 268 (1995) 286-290
20. Lawler S., Cuenda A., Goedert M., and Cohen P. SKK4, a novel activator of stress-activated protein kinase-1 (SAPK1/JNK). FEBS Lett. 414 (1997) 153-158
21. Lu X., Nemoto S., and Lin A. Identification of c-Jun NH2-tenninal protein kinase (JNK)-acti-vating kinase 2 as an activator of JNK but not p38. J. Biol. Chem. 272 (1997) 24751-24754
22. Tournier C., Whitmarsh A., Cavanagh J., Barrett T., and Davis R. Mitogen-activated protein kinase kinase 7 is an activator of the c-Jun NH2-terminal kinase. Proc. Natl. Acad. Sci., USA 94 (1997) 7342-7737
23. Wu A., Wu J., Jacinto E., and Karin M. Molecular cloning and characterization of human JNKK2, a novel Jun NH2-terminal kinase-specific kinase. Mol. Cell. Biol. 17 (1997) 7407-7416
24. Foltz I.N., Gerl R.E., Wieler J.S., Lyckach M., Salmon R.A., and Schrader J.W. Human mitogen-activated protein kinase kinase 7 (MKK7) is a highly conserved c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) activated by environmental stresses and physiological stimuli. J. Biol. Chem. 273 (1998) 9344-9351
25. Tibbies L.A., and Woodgett J.R. The stress-activated protein kinase pathways. Cell. Mol. Life. Sci. 55 (1998) 1230-1254
26. Xia Z., Dickens M., Raingeaud J., Davis R.J., and Greenberg M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270 (1995) 1326-1331
27. Kanamoto T., Mota M., Takefa K., Rubin L., Miyazono K., Ichijo H., and Bazenet C. Role of apoptosis signal-regulating kinase in regulation of the c-Jun N-terminal kinase pathway and apoptosis in sympathetic neurons. Mol. Cell. Biol. 20 (2000) 196-204
28. Teramoto H., Coso O.A., Miyata H., Igishi T., Miki T., and Gutkind J.S. Signaling from the small GTP-binding proteins Racl and Cdc42 to the c-Jun N-terminal kinase/stress-activated protein kinase pathway. A role for mixed lineage kinase 3/protein tyrosine kinase I, a novel member of the mixed lineage kinase family. J. Biol. Chem. 271 (1996) 27225-27228
29. Bazenet C.E., Mota M.A., and Rubin L.L. The small GTP-binding protein Cdc42 is required for nerve growth factor withdrawal-induced neuronal death. Proc. Natl. Acad. Sci., USA 95 (1998) 3984-3989
30. Yang D.D., Kuan C.Y., Whitmarsh A.J., Rincon M., Zheng T.S., Davis R.J., Rakic P., and Flavell R.A. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 389 (1997) 865-870
31. Behrens A., Sibilia M., and Wagner E.F. Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation. Nature Genetics 21 (1999) 326-329
32. Brecht S., Gass P., Anton F., Bravo R., Zimmermann M., and Herdegen T. Induction of c-Jun and suppression of CREB transcription factor proteins in axotomized neurons of substantia nigra and covariation with tyrosine hydroxylase. Mol. Cell. Neurosci. 5 (1994) 431-441
33. Brecht S., Martin-Villalba A., Zuschratter W., Bravo B., and Herdegen T. Transection of rat fimbria-fornix induces lasting expression of c-Jun protein in axotomized septal neurons immunonegative for choline acetyltransferase and nitric oxide synthase. Experimental Neurology 134 (1995) 112-125
34. Ferrer I., Pozas E., Ballabriga J., and Planas A.M. Strong c-.lun/AP-1 immunoreactivity is restricted to apoptotic cells following intracerebral ibotenic acid injection in developing rats. Neurosci. Res. 28 (1997) 21-31
35. Jenkins R., O'Shea R., Thomas K.L., and Hunt S.P. C-Jun expression in substantia nigra neurons following striatal 6-hydroxydopamine lesions in the rat. Neurosci. 53 (1993) 447-455
36. Butterworth N.J., and Dragunow M. Medial septal cholinergic neurons express c-Jun but do not undergo DNA fragmentation after fornix-fimbria transections. Mol. Brain Res. 43 (1996) 1-12
37. Leah J.D., Herdegen T., and Bravo R. Selective expression of Jun proteins following axotomy and axonal-transport block in peripheral nerves in the rat- evidence for a role in the regeneration process. Brain Res. 566 (1991) 198-207
38. Defelipe C., and Hunt S.P. The differential control of c-Jun expression in regenerating sensory neurons and their association with glial cells. J. Neurosci. 14 (1994) 2911-2923
39. Draganow M., Beilharz E., Sirimane E., Lawlor P., Williams C., Brave R., and Gluckman P. Immediate-early gene protein expression in neurons undergoing delayed death, but not necrosis, following hypoxic-ischemic injury to the young rat brain. Mol. Brain Res. 25 (1994) 19-33
40. Mielke K., Brecht S., Dorst A., and Herdegen T. Activity and expression of JNK1, p38 and ERK kinases, c-Jun N-terminal phosphorylation, and c-jun promoter binding in the adult rat brain following kainate-induced seizures. Neuroscience 91 (1999) 471-483
41. Herdegen T., Claret F.X., Kallunli T., Martin-Villalba A., Winter C., Hunter T., and Karin M. Lasting N-terminal phosphorylation of c-Jun and activation of c-Jun N-terminal kinases after neuronal injury. J. Neurosci. 18 (1998) 5124-5135
42. Roffler-Tarlov S., Brown J.J., Tarlov E., Stolarov J., Chapman D.L., Alexiou M., and Pa-paioannou V.E. Programmed cell death in the absence of c-Fos and c-Jun. Development 122 (1996) 1-9
43. Dong C., Yang D.D., Wysk M., Whitmarsh A.J., Davis R.J., and Flavell R.A. Defective T cell differentiation in the absence of Jnk1. Science 282 (1998) 2092-2095
44. Yang D.D., Conze D., Whitmarsh A.J., Barrett T., Davis R.J., Rincon M., and Flavell R.A. Differentiation of CD4 + T cells to Thl cells requires MAP kinase JNK2. Immunity 9 (1998) 575-585
45. Kuan C.Y., Yang D.D., Samanta D.R., Davis R.J., Rakic P., and Flavell R.A. The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron 22 (1999) 667-676
46. Anderson A.J., Su J.H., and Cotman C.W. DNA damage and apoptosis in Alzheimer's disease: Colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay. J. Neurosci. 16 (1996) 1710-1719
47. Reynolds C.H., Utton M.A., Gibb G.M., Yates A., and Anderton B.H. Stress-activated protein kinase/c-Jun N-terminal kinase phosphorylates x protein. J. Neurochem. 68 (1997) 1736-1744
48. Kase H., Iwahashi K., and Matsuda Y. K-252a, A potent inhibitor of protein kinase C from microbial origin. J. Antibiot. (Tokyo) 39 (1986) 1059-1065
49. Kase H., Iwahashi K., Nakanishi S., Matsuda Y., Yamada K., Takahashi M., Murakata C., Sato A., and Kaneko M. K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases. Biochem. Biophys. Res. Commun. 142 (1987) 436-440
50. Knusel B., and Hefti F. K-252 compounds: modulators of neurotrophic signal transduction. J. Neurochem. 59 (1992) 1987-1996
51. Maroney A.C., Lipfert L., Forbes M.E., Glicksman M.A., Neff N.T., Siman R., and Dionne C.A. K-252a induces tyrosine phosphorylation of the focal adhesion kinase and neurite outgrowth in human neuroblastoma SH-SY5Y cells. J. Neurochem. 64 (1995) 540-549
52. Borasio G.D. Differential effects of the protein kinase inhibitor K-252a on the in vitro survival of chick embryonic neurons. Neurosci. Lett. 108 (1990) 207-212
53. Glicksman M.A., Prantner J.E., Meyer S.L., Forbes M.E., Dasgupta M., Lewis M.E., and Neff N.T. K-252a and staurosporine promote choline acetyltransferase activity in rat spinal cord culture. J. Neurochem. 61 (1993) 210-221
54. Glicksman M.A., Forbes M.E., Prantner J.E., and Neff N.T. K-252a promotes survival and choline acetyltransferase activity in striatal and basal forebrain neuronal cultures. J. Neurochem. 64 (1995) 1502-1512
55. Cheng B., Barger S.W., and Mattson M.P. Staurosporine, K-252a and K-252b stabilize calcium homeostasis and promote survival of CNS neurons in the absence of glucose. J. Neurochem. 62 (1994) 1319-1329
56. Goodman Y., and Mattson M.P. Staurosporine and K-252a compounds protect hippocampal neurons against amyloid β-peptide toxicity and oxidative injury. Brain Res. 650 (1994) 170-174
57. Rotella D.P., Glicksman M.A., Pranter J.E., Neff N.T., and Hudkins R.L. The effect of pyrrolo[3,4-c]carbazole derivatives on spinal cord ChAT activity. Bioorg. Med. Chem. Lett. 5 (1995) 1167-1171
58. Matsuda Y., and Fukuda J. Inhibition by K-252a, a new inhibitor of protein kinase, of nerve growth factor-induced neurite outgrowth of chick embryo dorsal root ganglion cells. J. Neurosci. Lett. 87 (1988) 11-17
59. Hashimoto S. K-252a, a potent protein kinase inhibitor, blocks nerve growth factor-induced neurite outgrowth and changes in the phosphorylation of proteins in PC 12 cells. J. Cell Biol. 107 (1988) 1531-1539
60. Berg M.M., Sternberg D.W., Parada L.F., and Chao M.V. K-252a inhibits nerve growth factor-induced trk proto-oncogene tyrosine phosphorylation and kinase activity. J. Biol. Chem. 267 (1992) 13-16
61. Tapley P., Lamballe F., and Barbacid M. K-252a is a selective inhibitor of the tyrosine protein kinase activity of the trk family of oncogenes and neurotrophin receptors. Oncogene 7 (1992) 371-381
62. Ohmichi M., Decker S.J., Pang I., and Saltiel A.R. Inhibition of the cellular actions of nerve growth factor by staurosporine and K-252a results from the attenuation of the activity of the trk tyrosine kinase. Biochemistry 31 (1992) 4034-4039
63. Muroya K., Hashimoto Y., Hattori S., and Nakamuru S. Specific inhibition of NGF receptor tyrosine kinase activity by K-252a. Biochim. Biophys. Acta. 1135 (1992) 353-356
64. Nye S.H., Squinto S.P., Glass D.J., Stitt T.N., Hantzopoulos P., Macchi M.J., Lindsaay N.S., Ip N.Y., and Yancopoulos G.D. K-252a and staurosporine selectively block autopho-sphorylation of neurotrophin receptors and neurotrophin-mediated responses. Mol. Biol. Cell 3 (1992) 677-686
65. Kaneko M., Saito Y., Saito H., Matsumoto T., Matsuda Y., Vaught J.L., Dionne C.A., Angeles T.A., Glicksman M.A., Neff N.T., Rotella D.P., Kauer J.C., Mallamo J.P., Hudkins R.L., and Murakata C. Neurotrophic 3,9-Alkylthiomethyl- and -Alkoxymethyl-K-252a derivatives. J. Med. Chem. 40 (1997) 1863-1869
66. Angeles T.S., Steffler C., Bartlett B.A., Hudkins R.L., Stephens R.M., Kaplan D.R., and Dionne C.A. Enzyme linked immunosorbant assay for Trk A tyrosine kinase activity. Anal. Biochem. 236 (1996) 49-55
67. Kase H., Iwahashi K., Nakanishi S., Matsuda Y., Yamada K., Takahashi M., Murakata C., Sato A., and Kaneko M. K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases. Biochem. Biophys. Res. Commun. 142 (1987) 436-440
68. Borasio G.D., Hostmann S., Anneser J.M.H., Neff N.T., and Glicksman M.A. CEP-1347/KT7515, a JNK pathway inhibitor supports the in vitro survival of chick embryonic neurons. NeuroReport 9 (1998) 1435-1439
69. Maroney A.C., Glicksman M.A., Basma A.N., Walton K.M., Knight Jr. E., Murphy C.A., Bartlett B.A., Finn J.P., Angeles T., Matsuda Y., Neff N.T., and Dionne C.A. Motoneuron apoptosis is blocked by CEP-1347 (KT-7515), a novel inhibitor of the JNK signaling pathway. J. Neurosci. 18 (1998) 104-111
70. Cornelia J.X., Sanz-Rodriguez C., Aldea M., and Esquerda J.E. Skeletal muscle-derived trophic factors prevent motoneurons from entering an active cell death program in vitro. J. Neurosci. 14 (1994) 2674-2686
71. Milligan C.E., Oppenheim R.W., and Schwartz L.M. Motoneurons deprived of trophic support in vitro require new gene expression to undergo programmed cell death. J. Neurohiol. 25 (1994) 1005-1016
72. Arakawa Y., Sendtner M., and Thoenen H. Survival effect of ciliary neurotrophic factor (CNTF) on chick embryonic motoneurons in culture: Comparison with other neurotrophic factors and cytokines. J Neurosci. 10 (1990) 3507-3515
73. Hughes R.A., Sendtner M., and Thoenen H. Members of several gene families influence survival of rat motoneuronsin vitro and in vivo. J. Neurosci. Res. 36 (1993) 663-671
74. Henderson C.E., Camu W., Mettling C., Gouin A., Poulsen K., Karihaloo M., Rullamas J., Evans T., McMahon S.B., Armaini M.P., Berkemeier L., Phillips H.S., and Rosenthal A. Neurotrophins promote motor neuron survival and are present in embryonic limb bud. Nature 363 (1993) 266-270
75. Henderson C.E., Phillips H.S., Pollock R.A., Davies A.M., Lemeulle C., Armanini M., Simpson L.C., Moffet B., Vandlen R.A., Koliatsos V.E., and Rosenthal A. GDNF: A potent survival factor for motoneurons present in peripheral nerve and muscle. Science 266 (1994) 1062-1064
76. Maroney A.C., Glicksman M.A., Basma A.N., Walton K.M., Knight E., Murphy C.A., Bartlett B.A., Finn J.P., Angeles T., Matsuda Y., Neff N.T., and Dionne C.A. Motoneuron apoptosis is blocked by CEP-1347, a novel inhibitor of the JNK signaling pathway. J. Neurosci. 18 (1998) 104-111
77. Rosette C., and Karin M. Ultraviolet light and osmotic stress: Activation of the JNK cascade through multiple growth factor and cytokine receptors. Science 274 (1996) 1194-1197
78. Zanke B.W., Boudreau K., Rubie E., Winnett E., Tibbies L.A., Zon L., Kyriakis J., Liu F.-F., and Woodgett J.R. The stress-activated protein kinase pathway mediates cell death following injury induced bycis-platinum, UV irradiation or heat. Current Biol. 6 (1996) 606-613
79. Raingeaud J., Gupta S., Rogers J.S., Dickens M., Han J., Ulevitch R.J., and Davis R.J. Proinflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J. Biol. Chem. 270 (1996) 7420-7426
80. Rouse J., Cohen P., Trigon S., Morange M., Alonso-Llamazares A., Zamanillo D., Hunt T., and Nebreda A.R. A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 78 (1994) 1027-1037
81. Cuenda A., Rouse J., Doza Y.R., Meier R., Cohen P., Gallagher T.F., Young P.R., and Lee J.C. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 364 (1995) 229-233
82. Coyle J.T., and Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 262 (1993) 689-694
83. Williams L.R. Oxidative stress, age-related neurodegeneration and the potential for neurotrophic treatment. Cerebrovasc. Brain Metah. Rec. 7 (1993) 55-73
84. Schapira A.H.V. Oxidative stress in Parkinson's Disease. Neuropathol. Appl. Neurohiol. 21 (1995) 3-9
85. Maroney A.C., Finn J.P., Bozyczko-Coyne D., O'Kane T., Neff N.T., Tolkovsky A.M., Park D.S., Yan C.Y.I., Troy C.M., and Greene L.A. CEP-1347 (KT7515), an inhibitor of JNK activation, rescues sympathetic neurons and neuronally differentiated PC 12 Cells from death evoked by three distinct insults. J. Neurochem. 73 (1999) 1901-1912
86. Park D.S., Morris E.J., Stefanis L., Troy C.M., Shelanski M.L., Geller H.M., and Greene L.A. Multiple pathways of neuronal death induced by DNA-damaging agents, NGF deprivation, and oxidative stress. J. Neurosci. 18 (1998) 830-840
87. Liu Y., Gorospe M., Yang C., and Holbrook N.J. Role of mitogen activated protein kinase phosphatase during the cellular response to genotoxic stress. J. Biol. Chem. 270 (1995) 8377-8380
88. Chen Y.R., Wang X., Templeton D., David R.J., and Tan T.H. The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and y radiation. J. Biol. Chem. 271 (1996) 31929-31936
89. Troy C.M., Stefanis L., Prochiantz A., Greene L.A., and Shelanski M.L. The contrasting roles of ICE family proteases and interleukin 1-β in apoptosis induced by trophic factor withdrawal and by copper/zinc superoxide dismutase down-regulation. Proc. Natl. Acad. Sci. USA 93 (1996) 5635-5640
90. Troy C.M., Stefanis L., Greene L.A., and Shelanski M.L. Mechanisms of neuronal degeneration: A final common pathway?. Neurol. 72 (1997) 103-111
91. Troy C.M., Stefanis L., Greene L.A., and Shelanski M.L. Nedd2 is required for apoptosis after trophic factor withdrawal, but not superoxide dismutase (SOD-1) down regulation, in sympathetic neurons and PC12 cells. J. Neurosci. 17 (1997) 1911-1918
92. Green D.R., and Scott D.W. Activation-induced apoptosis in lymphocytes. Curr. Opin. Immunol. 6 (1994) 476-487
93. Gardner A.M., and Johnson G.L. Fibroblast growth factor-2 suppression of tumor necrosis factor α-mediated apoptosis requires RAS and the activation of mitogen-activated protein kinase. J. Biol. Chem. 271 (1996) 14560-14566
94. Liu A.-G., Hsu H., Goeddel D.V., and Karin M. Dissection of TNF receptor I effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death. Cell 87 (1996) 565-576
95. Verheij M., Bose R., Lin X.H., Yao B., Jarvis W.D., Grant S., Birrer M.J., Szabo E., Zon L.I., Kyriakis J.M., Halmovitz-Friedman A., Fuks A., and Kolesnick R.N. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 380 (1996) 75-79
96. Lenczowski J.M., Dominguez L., Eder A.M., King L.B., Zacharchuk C.M., and Ashwell J.D. Lack of a role for Jun kinase and AP-1 in Fas-induced apoptosis. Mol. Cell. Biol. 17 (1997) 170-181
97. Faris M., Kokot N., Latinis K., Kasibhatla S., Green D.R., Koretzky G.A., and Nel A. The c-Jun N-terminal kinase cascade plays a role in stress-induced apoptosis in Jurkat cells by up-regulating Fas ligand expression. J. Immunology 160 (1998) 134-144
98. Abreu-Martin M.T., Palladino A.A., Faris M., Carramanzana N.M., Nel A.E., and Targan S.R. Fas activates the JNK pathway in human colonic epithelial cells: lack of a direct role in apoptosis. Am. J. Physiol. 276 (1999) 599-605
99. Glicksman M.A., Chiu A.Y., Dionne C.A., Kaneko M., Murakata C., Oppenheim R.W., Prevette D., Sengelaub D.R., Vaught J.L., and Neff N.T. CEP-1347/KT-7515 prevents motor neuronal programmed cell death and injury-induced dedifferentation in vivo. J. Neurohiol. 35 (1998) 361-370
100. Chu-Wang L.-W., and Oppenheimer R.W. Cell death of motor neurons in the chick embryo spinal cord. J. Comp. Neurol. 777 (1978) 33-57
101. Nordeen E.J., Nordeen K.W., Sengelaub D.R., and Arnold A.P. Androgens prevent normally occurring cell death in a sexually dimorphic spinal nucleus. Science 229 (1985) 671-673
102. Oppenheim R.W. Cell death during development of the nervous system. Ann. Rev. Neurosci. 14 (1991) 453-501
103. Bartus R.T., Dean R.L., Beer B., and Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 217 (1982) 408-414
104. Dunnett S.B., Everitt B.J., and Robbins T.W. The basal forebrain-cortical cholinergic system: interpreting the function consequences of excitotoxic lesions. Trends Neurosci. 14 (1991) 494-501
105. Fibiger H.C. The organization and some projections of cholinergic neurons of the mammalian forebrain. Brain Res. Rev. 4 (1982) 327-388
106. Fibiger H.C. Cholinergic mechanisms in learning memory and dementia: a review of recent evidence. Trends Neurosci. 14 (1991) 220-223
107. Whitehouse P.J., Price D.L., Struble R.O., Clark A.W., and Delong M.R. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 215 (1982) 237-1239
108. Olton D.S., and Wenk G.L. Dementia: animal models of the cognitive impairments produced by degeneration of the basal forebrain cholinergic system. In: Meltzer H.Y. (Ed). Psychopharma-cology: The Third Generation of Progress (1987), Raven Press, New York 941-953
109. Smith G. Animal models of Alzheimer's disease: experimental cholinergic denervation. Brain Res. Rev. 13 (1988) 103-118
110. Bartus R.T. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp. Neurol. 163 (2000) 495-529
111. Murray C.L., and Fibiger H.C. Pilocarpine and physostigmine attenuate spatial memory impairments produced by lesions of the NBM. Behav. Neurosci. 100 (1986) 23-32
112. Mandel R.J., Gage F.H., and Thai L.J. Spatial learning in rats: correlation with cortical choline acetyltransferase and improvement with NGF following nbm damage. Exp. Neurol. 104 (1989) 208-217
113. Lindefors N., Boatel M.L., Mahy N., and Persson H. Widespread neuronal degeneration after ibotenic acid lesioning of cholinergic neurons in the nucleus basalis revealed by in situ hybridization. Neurosci. Lett. 135 (1992) 262-264
114. Coyle J.T. AD: a disorder of cortical cholinergic innervation. Science 219 (1983) 1184-1190
115. Wenk G.L., Harrington C.A., Tucker D.A., Ranee N.E., and Walker L.C. Basal forebrain neurons and memory: A biochemical, histological, and behavioral study of differential vulnerability to ibotenate and quisqualate. Behav. Neurosci. (1992) 909-923
116. Saporito M.S., Brown E.R., Miller M.S., Murakata C., Neff N.H., Vaught J.L., and Carswell S. Preservation of cholinergic activity and prevention of neuron death by CEP-1347/KT-7515 following excitotoxic injury of the nucleus basalis magnocellularis. Neuroscience 86 (1998) 461-472
117. Carlsen J., Zaborszky L., and Heimer L. Cholinergic projections from the basal forebrain to the basolateral amygdaloid complex: A combined retrograde fluorescent and immunohistochemical study. J. Comp. Neurol. 234 (1985) 155-167
118. Mcgaughy J., Kaiser T., and Sarter M. Behavioral vigilance following infusions of 192 IgG-saporin into the basal forebrain: selectivity of the behavioral impairment and relation to cortical AChE-positive fiber density. Behav. Neurosci. 110 (1996) 247-265
119. Muir J.L., Dunnett S.B., Robbins T.W., and Everitt B.J. Attentional functions of the forebrain cholinergic systems: effects of intraventricular hemicholinium, physostigmine, basal forebrain lesions and intracortical grafts on a multiple-choice serial reaction time task. Exp. Brain Res. 89 (1992) 611-622
120. Muir J.L., Everitt B.J., and Robbins T.W. AMPA-induced excitotoxic lesions of the basal forebrain: a significant role for the cortical cholinergic system in attentional function. J. Neurosci. 14 (1994) 2313-2326
121. Torres E.M., Perry T.A., Blockland A., Wilkinson L.S., Wiley R.G., Lappi D.A., and Dunnet S.B. Behavioural, histochemical and biochemical consequences of selective immunolesions in discrete regions of the basal forebrain cholinergic system. Neuroscience 63 (1994) 95-122
122. Vargo J.M., Lai H.V., and Marshall J.F. Light deprivation accelerates recovery from frontal cortical neglect: relation to locomotion and striatal Fos expression. Behav. Neurosci. 112 (1998) 387-398
123. Parasuraman R., and Haxby J.V. Attention and brain function in Alzheimer's Disease: a review. Neuropsychology 7 (1993) 242-272
124. Tierney M.C., Szalai J., Snow W.G., Fisher R.H., Nores A., Nadon G., Dunn E., and George-Hyslop St.P.H. Prediction of probable Alzheimer's disease in memory-impaired patients: A prospective longitudinal study. Neurology 46 (1996) 661-665
125. Dekker A.J., and Thai L.J. Effect of delayed treatment with nerve growth factor on choline acetyltransferase activity in the cortex of rats with lesions of the nucleus basalis magno-cellularis: dose requirements. Brain Res. 584 (1992) 55-63
126. Dekker A.J., Winkler J., Ray J., Thai L.J., and Gage F.H. Grafting of nerve growth factor-producing fibroblasts reduces behavioral deficits in rats with lesions of the nucleus basalis magnocellularis. Neuroscience 60 (1994) 299-309
127. Haroutunian V., Kanof P.D., and Davis K.L. Attenuation of nucleus basalis of Meynert lesion-induced cholinergic deficits by nerve growth factor. Brain Res. 487 (1989) 200-203
128. Hu L., Cote S.L., and Cuello C. Differential modulation of the cholinergic phenotype of the nucleus basalis magnocelluaris neurons by applying NGF at the cell body or cortical terminal fields. Exp. Neurol. 143 (1997) 162-171
129. DiCamillo A.M., Neff N.T., Carswell S., and Haun F.A. Chronic sparing of delayed alternation performance and choline acetyltransferase activity by CEP-1347/KT-7515 in rats with lesions of nucleus basalis magnocellularis. Neuroscience 86 (1998) 473-483
130. Dunnett S.B., and Barth T.M. Animal models of Alzheimer's disease and dementia (with an emphasis on cortical cholinergic systems). In: Willner P. (Ed). Behavioural Models in Psychopharmacology (1991), Cambridge University Press, London 359-418
131. Gage F.H., Armstrong D.M., Williams L.R., and Varon S. Morphological response of axotomized septal neurons to nerve growth factor. J. Comp. Neurol. 269 (1988) 147-155
132. Koliatsos V.E., Applegate M.D., Knusel B., Junard E.O., Burton L.E., Mobley W.C., Hefti F.F., and Price D.L. Recombinant human nerve growth factor prevents retrograde degeneration of axotomized basal forebrain cholinergic neurons in the rat. Exp. Neurol. 112 (1991) 161-173
133. Harper S.J., Saporito M.S., Hewson L., Young L., Smith D., Rigby M., Jackson P., Curtis N., Swain C., Hefti F., Vaught J.L., and Sirinathsinghji D. CEP-1347 increases ChAT activity in culture and promotes cholinergic neurone survival following fimbria-fornix lesion. Neuroreport 11 (2000) 2271-2276
134. Mesulam M.M. Human brain cholinergic pathways. Prog. Brain Res. 84 (1990) 231-241
135. Williams L.R., Inouye G., Cummins V., and Pelleymounter M.A. Glial cell line-derived neurotrophic factor sustains axotomized basal forebrain cholinergic neurons in vivo: doseresponse comparison to nerve growth factor and brain-derived neurotrophic factor. J. Pharmacol. Exp. Ther. 277 (1996) 1140-1151
136. Knusel B., Beck K.D., Winslow J., Rosenthal A., Burton L.E., Widmer H.R., Nikolics K., and Hefti F. Brain-derived neurotrophic factor administration protects basal forebrain cholinergic but not nigral dopaminergic neurons from degenerative changes after axotomy in the adult rat brain. J. Neurosci. 12 (1992) 4391-4402
137. Hefti F. Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transactions. J. Neurosci. 6 (1986) 2155-2162
138. Agid Y. Parkinson's disease: pathophysiology. The Lancet 337 (1991) 1321-1324
139. Langston J.W. The etiology of Parkinson's disease with emphasis on the MPTP story. Neurology 47 (1996) S153-S160
140. Graybiel A.M., Hirsch E.C., and Agid Y. The nigrostriatal system in Parkinson's disease. Adv. Neurol. 53 (1990) 17-29
141. Jenner P. The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 45 (1995) S6-12
142. Emilien G., Maloteaux J.M., Geurts M., Hoogenberg K., and Cragg S. Dopamine receptorsphysiological understanding to therapeutic intervention potential. Pharmacol. Ther. 84 (1999) 133-156
143. Heikkila R.E., Manzino L., Cabbat F.S., and Duvoisin R.C. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311 (1984) 467-469
144. Heikkila R.E., Hess A., and Duvoisín R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in mice. Science 224 (1984) 1451-1453
145. Blanchet P.J., Konitsiotis S., Hyland K., Arnold L.A., Pettigrew K.D., and Chase T.N. Chronic exposure to MPTP as a primate model of progressive parkinsonism: a pilot study with a free radical scavenger. Exp. Neurol. 153 (1998) 214-222
146. Jackson-Lewis V., Jakowec M., Burke R.E., and Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Neurodegeneration 4 (1995) 257-269
147. Javitch J.A., D'Amato R.J., Strittmatter S.M., and Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Nail. Acad. Sci. U.S.A. 82 (1985) 2173-2177
148. Tipton K.F., and Singer T.P. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 61 (1993) 1191-1206
149. Saporito M.S., Heikkila R.E., Youngster S.K., Nicklas W.J., and Geller H.M. Dopaminergic neurotoxicity of 1-methyl-4-phenylpyridinium analogs in cultured mesencephalon: relationship to dopamine uptake affinity and inhibition of mitochondrial respiration. J. Pharmacol. Exp. Ther. 260 (1992) 1400-1409
150. Nicklas W.J., Vyas I., and Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine. Life Sci. 36 (1985) 2503-2508
151. Kindt M.V., Heikkila R.E., and Nicklas W.J. Mitochondrial and metabolic toxicity of 1-methyl-4-(2′-methylphenyl)-1, 2, 3, 6-tetrahydropyridine. J. Pharmacol. Exp. Ther. 242 (1987) 858-863
152. Vyas I., Heikkila R.E., and Nicklas W.J. Studies on the neurotoxicity of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium. J. Neurochem. 46 (1986) 1501-1507
153. Schapira A.H., Gu M., Taanman J.W., Tabrizi S.J., Seaton T., Cleeter M., and Cooper J.M. Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann. Neurol. 44 (1998) S89-S98
154. Swerdlow R.H., Parks J.K., Miller S.W., Turtle J.B., Trimmer P.A., Sheehan J.P., Bennett Jr. J.P., Davis R.E., and Parker Jr. W.D. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann. Neurol. 40 (1996) 663-671
155. Dipasquale B., Marini A.M., and Youle R.J. Apoptosis and DNA degradation induced by 1-methyl-4-phenylpyridinium in neurons. Biochem. Biophys. Res. Commun. 181 (1991) 1442-1448
156. Hartley A., Stone J.M., Heron C., Cooper J.M., and Schapira A.H. Complex I inhibitors induce dose-dependent apoptosis in PC12 cells; Relevance to Parkinson's disease. J. Neurochem. 63 (1994) 1987-1990
157. +) in ventral mesencephalic-striatal co-culture in rat. Neurosci. Lett. 170 (1994) 191-194
158. Tatton N.A., and Kish S.J. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 77 (1997) 1037-1048
159. +-induced apoptosis in numan SH-SY5Y neuroblastoma cells. J. Neurosci. Res. 55 (1999) 620-628
160. Offen D., Beart P.M., Cheung N.S., Pascoe C.J., Hocham A., Oorodin S., Melamed E., Bernard R., and Bernard O. Transgenic mice expressing human Bc1-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine neurotoxicity. Proc. Natl. Acad. Sci. USA 95 (1998) 5789-5794
161. Trimmer P.A., Smith T.S., Jung A.B., and Bennett J.P. Dopamine neurons from transgenic mice with knockout of the p53 gene resist MPTP neurotoxicity. Neurodegeneration 5 (1996) 233-239
162. Anglade P., Vyas S., Javoy-Agid F., Herrero M.T., Michel P.P., Marquez J., Mouaft-Prigent A., Ruberg M., Hirsch E.C., and Agid Y. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol. 12 (1997) 25-31
163. Hunot S., Brugg B., Ricard D., Michel P.P., Muriel M.P., Ruberg M., Faucheux B.A., Agid Y., and Hirsch E.C. Nuclear translocation of NF-KappaB is increased in dopaminergic neurons of patients with Parkinson's disease. Proc. Natl. Acad. Sci. USA 94 (1997) 7531-7536
164. Saporito M.S., Brown E.M., Miller M.S., and Carswell S. CEP-1347/K.T-7515. An inhibititor of c-jun N-terminal kinase activation attenuates the 1-methyl-4-phenyl tetrahydropyridinemediated loss of nigrostriatal dopaminergic neurons in vivo. J. Pharmacol. Exp. Ther. 288 (1999) 421-427
165. Konitsiotis S., Saporito M.S., Flood D.G., Hyland K., Miller M., Lin Y.G., Arnold L.A., LePoole K., Bibbiani F., Blanchet P.J., and Chase T.N. The neuroprotective effects of CEP-1347 in a primate model of MPTP-induced chronic progressive parkinsonism. Soc. Neurosci. Abst. 25 (1999) 1595
166. Saporito M.S., Thomas B.A., and Scott R.W. MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo. J. Neurochem. 75 (2000) 1200-1208
167. + analogs and related charged species. J. Med. Chem. 33 (1990) 2221-2230
168. Cassarino D.S., Fall C.P., Swerdlow R.H., Smith T.S., Halvorsen E.M., Miller S.W., Parks J.P., Parker Jr. W.D., and Bennett Jr. J.P. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim. Biophys. Acta. 1362 (1997) 77-86
169. Chan P., DeLanney L.E., Irwin I., Langston J.W., and Di Monte D. Rapid ATP loss caused by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in mouse brain. J. Neurochem. 57 (1991) 348-351
170. Giovanni A., Sieber B.A., Heikkila R.E., and Sonsalia P.K. Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine administration to several strains of mice. J. Pharmacol. Exp. Ther. 257 (1991) 691-697
171. Vaglini F., Fascetti F., Tedeschi D., Cavalletti M., Fornai F., and Corsini G.U. Striatal MPP+ levels do not necessarily correlate with striatal dopamine levels after MPTP treatment in mice. Neurodegeneration 5 (1996) 129-136
172. Ofori S., Heikkila R.E., and Nicklas W.J. Attenuation by dopamine uptake blockers of the inhibitory effects of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine and some of its analogs on NADH-linked metabolism in mouse neostriatal slices. J. Pharmacol. Exp. Ther. 251 (1989) 258-266
173. Rollema H., Kuhr W.G., Kranenborg G., De Vries J., and Van den Berg C. MPP+-induced efflux of dopamine and lactate from rat striatum have similar time courses as shown by in vivo brain dialysis. J. Pharmacol. Exp. Ther. 245 (1988) 858-866
174. Pirvola U., Xing-Quin L., Virkkala J., Murakata C., Camoratta A.M., Walton J., and Ylikoski K.W. J. Neurosci. 20 (2000) 43-50